Market capitalization | $261.45m |
Enterprise Value | $298.50m |
P/E (TTM) P/E ratio | 55.47 |
EV/FCF (TTM) EV/FCF | 19.13 |
EV/Sales (TTM) EV/Sales | 1.54 |
P/S ratio (TTM) P/S ratio | 1.35 |
P/B ratio (TTM) P/B ratio | 7.31 |
Revenue growth (TTM) Revenue growth | 4.21% |
Revenue (TTM) Revenue | $193.66m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Zynex, Inc. forecast:
3 Analysts have issued a Zynex, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 194 194 |
4%
4%
|
|
Gross Profit | 154 154 |
4%
4%
|
|
EBITDA | 13 13 |
42%
42%
|
EBIT (Operating Income) EBIT | 8.85 8.85 |
52%
52%
|
Net Profit | 4.82 4.82 |
70%
70%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
Head office | United States |
CEO | Thomas Sandgaard |
Employees | 1,100 |
Founded | 1996 |
Website | www.zynex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.